Antiretroviral therapy (ART) quickly and persistently suppresses viral replication resulting in improved quality of life for people with human immunodeficiency virus/acquired immune deficiency syndrome (PWHA), reduced AIDS-associated death rates, reduced morbidity events, and increased life expectancy \[[@CIT0001]\]. However, treatment is life-long with several limitations \[[@CIT0002]\]. If treatment is interrupted, plasma viral load (VL) rapidly rebounds, due to the persistence of long-lived and proliferating latently infected cells that persist on ART \[[@CIT0003], [@CIT0004]\].

Because of overlapping pathways of transmission between HIV and hepatitis C virus (HCV), approximately 2 to 5 million individuals worldwide are estimated to be coinfected \[[@CIT0005], [@CIT0006]\]. In Argentina, coinfected individuals represent approximately 20% of PWHA \[[@CIT0007]\]. Hepatitis C virus direct antiviral agents (DAAs), which target specific steps of HCV replication cycle, represent a major development in the treatment of HCV, with the possibility of \>95% of cure and low rate of adverse events, even with advanced or decompensated cirrhosis \[[@CIT0008]\]. The DAA-mediated clearance of HCV is associated with loss of intrahepatic immune activation by interferon (IFN)-α, recovery of T-cell proliferation, normalization of natural killer (NK)-cell phenotype and function \[[@CIT0009]\], and restoration of type I IFN response both in acute \[[@CIT0010]\] and chronic \[[@CIT0011]\] HCV infection, as well as enhanced HCV-specific CD8^+^ T-cell responses \[[@CIT0012]\].

Understanding the interaction between HCV coinfection before and after clearance of HCV on the HIV reservoir is important, because HIV/HCV coinfection is common and the high cure rate after DAAs allows for the opportunity to assess the impact of HCV on HIV persistence. Hepatitis C virus/HIV coinfection has been associated with increased levels of immune activation compared with HIV monoinfection including higher levels of microbial products \[[@CIT0013], [@CIT0014]\], low levels of detectable plasma HIV in PWHA on ART \[[@CIT0015], [@CIT0016]\], and increased risk of HIV virological failure \[[@CIT0017]\]. Early reports showed that cell-associated (CA) HIV ribonucleic acid (RNA) levels decreased after HCV treatment with IFN-α plus ribavirin (RBV) \[[@CIT0018]\], whereas no effect \[[@CIT0018]\] or a decrease \[[@CIT0019], [@CIT0020]\] was observed in HIV DNA. More recent studies have reported an increase in CD4^+^ T cells harboring integrated HIV deoxyribonucleic acid (DNA) in HIV/HCV even after spontaneous HCV clearance \[[@CIT0021]\], whereas DAA-mediated HCV clearance was associated with stable or increased levels of HIV CA DNA \[[@CIT0022], [@CIT0023]\].

We hypothesized that the elimination of HCV coinfection with DAAs would modulate the size and/or transcriptional activity of the HIV reservoir due to the restoration of HCV-driven immune dysregulation. We quantified the immediate and long-term effects of DAA-mediated HCV clearance in HIV/HCV-coinfected participants on multiple markers of immune function and on HIV persistence in blood. Overall, we observed a downmodulation of NK- and T-cell activation markers as well as of soluble plasma activation markers after treatment with DAAs. This was accompanied by an increase in peripheral CA HIV unspliced (US)-RNA with no change in HIV DNA. These results suggest a relationship between HCV and transcriptional activity of the HIV reservoir.

METHODS {#s1}
=======

This was a longitudinal, single-center study approved by the local Ethics Committee of the Huésped Foundation (Buenos Aires, Argentina). All participants were included after signing the informed consent from March 17, 2016 to May 12, 2016, and samples were analyzed during 2017, 2018, and 2019. Sample sizes were determined using the Harris, Horvitz, and Mood method to provide 80% power, at the 5% level of significance. Peripheral blood from 19 ART-treated participants with HIV/HCV coinfection were collected at baseline (BSL) before the start of DAA, at the end of treatment (EOT) (either at completion of 12 or 24 weeks of DAA), and after 12 months of DAA termination (12MPT). At 12MPT, samples from 2 participants were not available due to lung cancer diagnosis and loss of follow up, respectively. All individuals received HCV treatment with sofosbuvir (SOF) and daclatasvir (DCV), and 12 participants also received ribavirin (RBV). Diagnosis of liver cirrhosis was made by liver biopsy or hepatic transient elastography (\>14 kPa). No participants had signs of hepatic decompensation at the time of enrollment. Sustained virological response (SVR) to DAA was defined by nondetectable HCV RNA (lower limit of detection, 12 IU/mL) at 12 weeks after EOT. Hepatitis C virus RNA was also evaluated at 48 weeks after EOT and it was nondetectable in all cases. Inclusion criteria were successful ART with HIV VL \<40 copies/mL for more than 24 months. Peripheral blood mononuclear cells (PBMCs) were obtained from 60 mL whole blood by Ficoll-Hypaque density gradient centrifugation (GE Healthcare, UK) and cryopreserved in liquid nitrogen.

Cell-associated HIV RNA (US and multiple-spliced \[MS\]) and DNA forms (total HIV, HIV-integrated, and 2LTR circles) were evaluated in sorted CD4^+^ T cells by quantitative real-time polymerase chain reaction (PCR), as described previously \[[@CIT0024]\]. Ultrasensitive HIV plasma VL was evaluated in all samples by replicate testing using the Aptima HIV-1 quant assay (Hologic). T-cell and NK-cell phenotyping was performed by flow cytometry. Soluble plasma factors were quantified by enzyme-linked immunosorbent assay. Detailed methods are described in [Supplementary Material S1](#sup8){ref-type="supplementary-material"}.

Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software) and InfoStat (UNC, Cordoba, Argentina) and R project (R Foundation for Statistical Computing, Vienna, Austria) softwares. Data were analyzed using nonparametric methods. Longitudinal association between CA US-HIV RNA and plasma RNA was estimated by using a generalized linear mixed-effects regression model. Correlation analyses were performed using Spearman's rank test. For the phenotypic analyses, SPICE 6.0 software (<https://niaid.github.io/spice/>) was used following the experimental and technical considerations published by the software developers \[[@CIT0025]\]. All tests were considered significant when *P* \< .05.

RESULTS {#s2}
=======

Study Group {#s3}
-----------

A total of 19 HIV/HCV-coinfected individuals were enrolled. Most participants were male (74%), and the median age was 49 years (interquartile range, 46--53). All participants were receiving ART with at least 2 years of documented undetectable HIV VL. During DAA, all individuals received integrase inhibitor-based ART. Sofosbuvir/DCV with RBV was prescribed for 12 weeks in 9 participants and 24 weeks in 3 participants, and 7 participants received SOF/DCV for 24 weeks without RBV. The use of RBV depended on HCV genotype and drug tolerance. All participants achieved SVR. Further clinical details are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Subjects Characteristics

  Characteristics                      BSL n = 19          EOT n = 19          12MPT n = 17        *P* Value^a,b^
  ------------------------------------ ------------------- ------------------- ------------------- ----------------
  Age (years)^c^                       49 (46--53)         \--                 49 (45--52)         \--
  Male sex (n, %)^d^                   14 (73.4)           \--                 13 (76.4)           \--
  CD4 count (cells/μL)^c^              291 (231--776)      460 (205--692)      506 (233--1058)     \>.999/.455
  CD8 count (cells/μL)^c^              849 (498--1263)     917 (407--1293)     1041 (503--1389)    .851/.216
  NK cells (%)^c^                      8.9 (5.6--16.2)     8.1 (5.7--39.6)     9.5 (4.2--28.2)     .903/.845
  CD4/CD8 ratio^c^                     0.56 (0.33--0.78)   0.52 (0.39--0.78)   0.51 (0.39--0.71)   .025/.397
  Time of HCV infection (years)^c^     13 (11--22)         \--                 \--                 \--
  Time of HIV infection (years)^c^     19 (12--21)         \--                 \--                 \--
  HCV viral load (log~10~ copies)^c^   5.89 (5.56--6.13)   All \<1.3           All \<1.3           \<.001/\<.001
  Time of ARV (years)^c^               10.5 (4--16.5)      \--                 \--                 \--
  Routes of Transmission (n, %)^d^                                                                 
   IDU                                 14 (73.7)           \--                 \--                 \--
   Heterosexual                        5 (21.1)            \--                 \--                 \--
   MSM                                 1 (5.3)             \--                 \--                 \--
  HCV Genotype (n, %)^d^                                                                           
   1a                                  12 (63.2)           \--                 \--                 \--
   1b                                  1 (5.3)             \--                 \--                 \--
   1                                   3 (15.8)            \--                 \--                 \--
   3                                   3 (15.8)            \--                 \--                 \--
  Liver stiffness (kPa)^c^             22.2 (17.9--32.2)   ND                  ND                  \--
  APRI score^c^                        1.16 (0.58--2.09)   0.76 (0.29--0.84)   0.55 (0.29--1.03)   .0084/.0004
  ALT (IU/L)^c^                        67.5 (46--82)       27 (17--49)         33 (24--49)         \<.001/\<.001
  AST (IU/L)^c^                        78.5 (68.2--93.7)   33 (26--45)         38 (32--51)         \<.001/\<.001
  Albumin (g/dL)^c^                    4.2 (3.6--4.5)      4.2 (3.9--4.4)      4.4 (4.1--4.5)      .382/.020
  Platelets (×10^3^/mm^3^)^c^          111 (98--213)       121 (87--229)       121 (77--193)       .922/.130
  Total bilirubin (μg/dL)^c^           0.85 (0.72--1.1)    0.80 (0.55--1.42)   0.80 (0.70--1.0)    .183/.450
  Prothrombin time (%)^c^              74 (63--93)         71 (63--81)         76 (69--85)         .531/.867

Abbreviations: 12MPT, 12 month post treatment; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio; ARV, antiretroviral therapy; AST, aspartate transaminase; BSL, baseline; EOT, end of treatment; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug user; MSM, men who have sex with men; ND, not determined; NK, natural killer.

^a^BSL vs EOT, Wilcoxon test.

^b^BSL vs 12MPT, Wilcoxon test.

^c^Median (interquartile range).

^d^Number of cases (number/total in %).

Human Immunodeficiency Virus Persistence After Direct-Acting Antiviral Treatment {#s4}
--------------------------------------------------------------------------------

We quantified the frequency and transcriptional activity of HIV-infected cells before (BSL sample) and after DAA treatment (EOT and 12MPT samples) as an indicator of HIV persistence. No statistically significant differences were observed in CA viral DNA (total, integrated, and 2LTR circles) ([Figure 1A](#F1){ref-type="fig"}), ie, overall levels remained stable from BSL to 12MPT. No differences in plasma HIV RNA, measured by ultrasensitive single-copy assay, were found among time points ([Figure 1B](#F1){ref-type="fig"}).

![Human immunodeficiency virus (HIV) reservoir dynamics in HIV/hepatitis C virus-coinfected individuals treated with direct-acting antivirals (DAA). Cell-associated (CA) HIV deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), as well as plasma HIV RNA were evaluated in coinfected individuals before treatment initiation (baseline \[BSL\]), at the end of treatment (EOT), and 12 months after finalizing DAA therapy (12MPT). The CA total HIV DNA, integrated DNA and 2LTR (A), CA multiple-spliced (MS)-RNA, unspliced (US)-RNA, and plasma RNA (B), and US-RNA/integrated DNA, US-RNA/total HIV DNA, and MS/US-RNA ratios (C) are shown. Viral DNA and RNA copies were calculated relative to 10^6^ cell equivalents (CE). Individual values, median and 25th and 75th percentiles, are indicated. Statistical comparisons were performed using Wilcoxon test, *P* \< 0.05.](ofaa115f0001){#F1}

Levels of CA MS-RNA remained low and stable along all the studied time points ([Figure 1B](#F1){ref-type="fig"}). However, a statistically significant increase in CA US-RNA was observed between BSL and 12MPT (*P* = 0.0203) ([Figure 1B](#F1){ref-type="fig"}). Of note, the higher increments in US-RNA were observed in those participants who did not receive RBV within their regimens ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}); US-RNA was higher at BSL in the RBV group, nevertheless no differences in any of the clinical or laboratory parameters were observed between both groups that could account for that disparity.

To provide further insight into the transcriptional activity of the infected cells, the ratio of CA US-RNA and both the integrated and total HIV DNA were calculated. In addition, the ratio between CA MS- and US-RNA was obtained to estimate the relative efficiency of transcriptional elongation and splicing. No differences were found among BSL, EOT, and 12MPT ([Figure 1C](#F1){ref-type="fig"}). Finally, we hypothesized that increased US-RNA, if associated with increased viral transcription, would be correlated with plasma RNA. The longitudinal study of CA US-HIV RNA and plasma RNA across all 3 time points evaluated depicted a potential association between both variables (*P* = 0.002) ([Figure 2](#F2){ref-type="fig"}).

![Association analysis between cell-associated (CA) unspliced (US) and plasma human immunodeficiency virus (HIV) ribonucleic acid (RNA) in HIV/hepatitis C virus-coinfected individuals treated with direct-acting antivirals (DAA). The CA US-RNA as well as plasma HIV RNA were evaluated in coinfected individuals before treatment initiation (baseline \[BSL\]), at the end of treatment (EOT), and 12 months after finalizing DAA therapy (12MPT). Relationship between variables was measured by applying a generalized linear mixed-effects model with plasma RNA as the independent variable and CA US-RNA and time as fixed-effect predictors; *P* value for the CA US-RNA coefficient is shown. White, gray, and black filled dots represent individual measures belonging to BSL, EOT, and 12MPT subgroups, respectively.](ofaa115f0002){#F2}

T-Cell Immune Phenotyping {#s5}
-------------------------

The profile of different memory subsets and the expression of different markers were studied on CD8^+^ and CD4^+^ T cells (gating strategy is shown in [Supplementary Figure S2](#sup2){ref-type="supplementary-material"}). We defined 6 CD8^+^ or CD4^+^ T-cell subpopulations: naive (T~Naive~, CCR7^+^CD45RO^−^CD28^+^CD95^−^), stem memory (T~SCM~, CCR7^+^CD45RO^−^CD28^+^CD95^+^), central memory (T~CM~, CCR7^+^CD45RO^+^CD28^+^CD95^+^), transitional memory (T~TM~, CCR7^−^CD45RO^+^CD28^+^CD95^+^), effector memory (T~EM~, CCR7^−^CD45RO^+^CD28^−^CD95^+^), and terminal effector (T~TE~, CCR7^−^CD45RO^−^CD28^−^CD95^+^) cells. The distribution of these subsets was analyzed as previously described \[[@CIT0026]\]. The memory profile within the CD4^+^ T-cell compartment showed the following hierarchical distribution: T~TM~ cells represented the highest proportions, followed by T~CM~, T~Naive~, T~EM~, T~SCM~, and T~TE~ cells ([Supplementary Figure S3A](#sup3){ref-type="supplementary-material"}). Regarding the CD8^+^ T-cell compartment, the distribution was as follows: T~EM~ cells comprised the highest proportions, followed by T~TE~, T~TM~, T~Naive~, T~CM~, and T~SCM~ cells ([Supplementary Figure S3B](#sup3){ref-type="supplementary-material"}). Memory distribution observed on both T-cell compartments were conserved across the 3 time points analyzed (BSL, EOT, and 12MPT), and no significant differences were observed between them.

We next quantified the expression of immune surface markers (such as CD38, HLA-DR, CD127, PD-1, and CD25) in both T-cell compartments. At BSL, elevated proportions of CD4^+^/HLA-DR^+^, CD4^+^/PD-1^+^, CD4^+^/CD38^+^/HLA-DR^+^, and CD4^+^/CD38^+^/HLA-DR^+^/PD-1^+^ T cells were observed. These proportions were significantly reduced by 12MPT ([Supplementary Figure S4A](#sup4){ref-type="supplementary-material"}). The decay in activation markers observed from BSL to 12MPT was observed in all CD4^+^ T-cell subpopulations, with CD4^+^ T~TM~ and T~EM~ having the largest and most significant changes.

A similar scenario was observed on CD8^+^ T cells. At BSL, higher proportions of CD8^+^ T cells expressing CD38 and HLA-DR were recorded. After DAA treatment, the expression of these activation markers was significantly reduced. The proportions of double-positive CD8^+^/CD38^+^/HLA-DR^+^ and triple-positive CD8^+^/CD38^+^/HLA-DR^+^/PD-1^+^ T cells were significantly reduced at EOT and 12MPT, respectively ([Supplementary Figure S5A](#sup5){ref-type="supplementary-material"}). Similar to the CD4^+^ T-cell compartment, the decay in CD38, HLA-DR, and PD-1 expression was observed in all CD8^+^ T-cell subpopulations ([Supplementary Figure S5B](#sup5){ref-type="supplementary-material"}). In this compartment, the subpopulations that exhibited more pronounced modifications after HCV clearance were the more differentiated phenotypes (CD8^+^ T~TM~, T~EM~, and T~TE~).

Natural Killer Cell Immune Phenotyping {#s6}
--------------------------------------

Compared with BSL, CD38 expression on NK cells was significantly reduced at EOT, and it continued at this lower level throughout the study ([Supplementary Figure S6A](#sup6){ref-type="supplementary-material"}). The frequency of HLA-DR-expressing NK cells was significantly reduced at EOT ([Supplementary Figure S5B](#sup5){ref-type="supplementary-material"}), whereas there was a slight increase by 12MPT levels, but it still remained at lower levels than those from BSL ([Supplementary Figure S6B](#sup6){ref-type="supplementary-material"}). When analyzing the distribution of NK-cell subsets defined by the expression of both HLA-DR and CD38, we found a significant reduction in the frequency of HLA-DR^+^/CD38^+^ NK cells, with a concomitant increase in the frequency of cells negative for both markers at EOT and 12MPT ([Supplementary Figure S6C](#sup6){ref-type="supplementary-material"}). In addition, the apoptosis-inducing receptor CD95 was studied. Percentages of CD95-expressing cells at EOT were lower than those from BSL; however, CD95 levels rebounded at 12MPT, reaching similar levels observed at BSL ([Supplementary Figure S6D](#sup6){ref-type="supplementary-material"}). Moreover, a trend towards a decreased frequency of both CD25^+^ and CD69^+^ NK cells at EOT and 12MPT was observed; however, neither CD25 nor CD69 expression differed among time points ([Supplementary Figure S6E](#sup6){ref-type="supplementary-material"} and [F](#sup6){ref-type="supplementary-material"}). It is interesting that, similar to our previous results, the frequency of CD25^+^/CD69^+^/CD95^+^ NK cells was reduced at EOT and 12MPT, whereas percentages of triple-negative NK cells were significantly augmented ([Supplementary Figure S6G](#sup6){ref-type="supplementary-material"}). Finally, expression of NK cell-activating receptor NKG2D and natural cytotoxic receptors (NCRs) NKp30 and NKp46 were evaluated. As shown in [Supplementary Figure S5H](#sup5){ref-type="supplementary-material"}, the percentage of NKG2D-expressing NK cells was significantly decreased at EOT, compared with BSL. When relative fluorescence intensities (RFIs) were examined, a significant reduction in NKG2D expression was also obtained at 12MPT ([Supplementary Figure S6H](#sup6){ref-type="supplementary-material"}, right panel). Regarding NCRs, although NKp46 expression was not differentially modulated, we observed a trend towards a reduction in the expression of NKp30 at EOT and 12MPT. No differences were found when analyzing RFI (Figure 6H).

Soluble Factors {#s7}
---------------

Then, plasma concentrations of different soluble factors, frequently associated with markers of immune activation and inflammation, were evaluated. Interleukin (IL)-17 and IL-1β were below the limit of detection so they could not be quantified. For IL-6, IL-2, soluble (s)CD14, IFN-γ, tumor necrosis factor-α, and sCD23, no differences were observed along the different time points evaluated ([Supplementary Figure S7A](#sup7){ref-type="supplementary-material"}−[F](#sup7){ref-type="supplementary-material"}). In contrast, IFN-inducible protein 10 (IP-10), IL-8 soluble intercellular adhesion molecule 1 (sICAM-1), and sCD163 were elevated at BSL but were significantly reduced at EOT (*P* \< 0.0001, *P* = 0.0015, *P* \< 0.0001, and *P* = 0.0002, respectively) and remained low (always compared with BSL) at 12MPT (*P* = 0.0107, *P* = 0.0426, *P* = 0.0001, and *P* = 0.002, respectively) ([Supplementary Figure S7G](#sup7){ref-type="supplementary-material"}−[J](#sup7){ref-type="supplementary-material"}).

Association Between Immune Status and Human Immunodeficiency Virus Persistence {#s8}
------------------------------------------------------------------------------

Finally, we assessed the relationship between the different immune parameters and HIV viral persistence. All immune measurements (T and NK phenotype and plasma soluble factors) evaluated at 12MPT were compared with US-RNA levels at 12MPT, the US-RNA fold-up between 12MPT and BSL (12MPT/BSL), and the US-RNA change (delta) between 12MPT and BSL (12MPT-BSL). For simplicity, results are shown in heat maps denoting r values. Significant correlations are highlighted, and the corresponding y versus x plot is shown. No statistically significant correlations were found between US-RNA at 12MPT, US-RNA fold-increase, or delta US-RNA with parameters evaluated on CD4^+^ or NK cells (data not shown). In contrast, US-RNA fold-increase was negatively associated with the proportions of CD8 T~TM~ cells and positively associated with %CD8 T~EM~ cells ([Figure 3A](#F3){ref-type="fig"}). Levels of most cytokines at 12MPT showed positive r values with the 3 virological parameters evaluated; however, only sCD163 showed a statistically significant correlation with delta US-RNA ([Figure 3B](#F3){ref-type="fig"}).

![Correlation analyses between cellular and soluble markers of immune activation and inflammation, and human immunodeficiency virus (HIV) reservoirs in HIV/hepatitis C virus-coinfected individuals treated with direct-acting antivirals (DAA). Heat map representation of Spearman rank correlation coefficients computed for the expression of CD8^+^ T-cell immune markers at 12 months after finalizing DAA therapy (12MPT) (A) and plasma levels of soluble factors of immune activation and inflammation at 12MPT (B) versus HIV unspliced (US)-ribonucleic acid (RNA) at 12MPT (US-RNA 12 MPT), US-RNA fold up between 12MPT and baseline (BSL) (Fold-up US-RNA 12MPT/BSL), and differences between US-RNA at 12MPT minus levels at BSL (Delta US-RNA 12MPT-BSL). The colors denote both the correlation direction and strength of association, ranging from −1 (blue) to 1 (red). Statistical significant associations are further shown below each panel in individual × vs y plots. Spermans's r and *P* values are shown. ICAM, intercellular adhesion molecule; IL, interleukin; IP-10, interferon-inducible protein 10; TNF, tumor necrosis factor.](ofaa115f0003){#F3}

DISCUSSION {#s9}
==========

Human immunodeficiency virus remission and cure clinical research has largely occurred in high-income settings where (1) most participants are men who have sex with men, (2) subtype B is the most prevalent viral variant, (3) malnutrition is not a regular finding, and (4) there is a low burden of coinfections. All of these factors may be important determinants of the size and transcriptional activity of the HIV reservoir, and cure strategies may need to be different for high- and low-middle income settings, especially if the intervention is dependent on a change in immune function \[[@CIT0027]\]. In this study, we found that DAA-mediated HCV clearance in HIV/HCV-coinfected subjects is associated with the following: a clear improvement in liver functionality and a tendency to improved CD4^+^ T cells counts; a decrease in the surface expression of activation and exhaustion markers in CD4^+^ and CD8^+^ T cells and in NK cells; lower plasma levels of IP-10 and IL-8 and indicators of macrophage and monocyte activation, such as sCD163 and sICAM; and higher levels of US-RNA at 12 months post-DAA treatment.

Therapies with DAAs are very effective oral and short-term treatments, with more than 90% of SVR, even in HIV-coinfected individuals \[[@CIT0028]\]. This has been reflected in our study, where all participants achieved viral clearance and improved liver function parameters, despite the presence of advanced hepatic disease. In addition, a recovery in both CD4^+^ and CD8^+^ T-cell phenotype (in terms of the expression of activation and exhaustion markers) was registered after DAA treatment. These findings are in line with previous reports after DAA for HIV/HCV coinfection describing improved HCV-specific CD8^+^ T-cell functionality and lower PD-1 expression, recovery of the CD4^+^ T-cell compartment, and a replenishment of T cells with memory/effector phenotype \[[@CIT0029]\]. Likewise, a decrease in the proportion of activated NK cells was found after DAA treatment, in agreement with previous publications describing reduced expression of activation markers and cytolytic activity \[[@CIT0009], [@CIT0029], [@CIT0031], [@CIT0032]\]. Although others have observed an increase in NK cell frequency after DAA treatment \[[@CIT0033]\], this was not found in our study. It might be because in this study, all individuals presented with end-stage liver fibrosis, which is linked to low NK cell frequencies \[[@CIT0034]\]. In these individuals, liver damage could be a stronger factor modifying NK-cell population than HCV clearance. Finally, lower levels of soluble inflammatory factors, such as IP-10, were previously reported \[[@CIT0038]\] and recapitulated in our study.

The first reports regarding the impact of HCV on HIV persistence on ART, described that IFN-α/RBV treatment was associated with decreased levels of total and integrated HIV DNA in CD4^+^ T cells \[[@CIT0020]\] and 2LTR circles from PBMCs \[[@CIT0019]\]---as assessed by reverse-transcription PCR---and also CD4^+^ T-cell HIV RNA reduction \[[@CIT0018]\]. In this latter report, no differences were found regarding CD4^+^ T-cell proviral HIV DNA, 2LTR circles, and replication-competent reservoirs measured with quantitative viral outgrowth assay (qVOA). Nevertheless, it is important to highlight that those therapies were based on 2 drugs (IFN-α and RBV) that could also have a direct effect on HIV replication \[[@CIT0039], [@CIT0040]\]. More recently, 3 studies have evaluated the levels of CA HIV DNA in PBMCs before and after DAAs for HCV treatment. Parisi et al \[[@CIT0022]\] described that there was an increase or decrease in total HIV DNA after DAA treatment depending on the magnitude of HIV viremia (low-level versus undetectable) before starting DAAs. In other works, HIV DNA remained stable before and after DAA treatment \[[@CIT0023], [@CIT0041]\]. All 3 forms of HIV DNA measured here (total, integrated, and 2LTR) remained stable during follow up. The differential findings might be explained by the use of purified CD4^+^ T cells instead of total PBMCs to quantify HIV DNA and a more rigorous criteria regarding HIV undetectable VL before enrollment. It is also worth noting that, although extensively used, PCR-based techniques for measuring both total and integrated HIV DNA face considerable limitations, because they tend to overestimate the size of the reservoir due to the high prevalence of defective proviruses. Thus, these results should not be interpreted as if there was no effect on the size of the competent reservoir \[[@CIT0042]\].

We also studied the transcriptional activity of infected cells by measuring US-RNA and MS-RNA and plasma RNA. A significant increase in US-RNA was found 12 months after HCV clearance with no increase in CA MS-RNA or plasma RNA levels. Correlation analysis indicated that the elevation of US-RNA was accompanied by diminished proportions of CD8^+^ T~TM~ cells and higher proportions of CD8^+^ T~EM~ cells. This could be an indicator that higher transcription might be accompanied by production of at least some viral proteins that might be priming memory CD8^+^ T-cell responses. On the other hand, the steady state of MS-RNA and plasma RNA levels could be reflecting a block in viral cycle termination. This raises different hypotheses. Higher levels of US-RNA might represent higher rates of genuine HIV transcripts but also host-HIV read-through transcripts \[[@CIT0043], [@CIT0044]\]. However, these latter transcripts have been shown to contribute poorly to the bulk of HIV RNA, so this hypothesis seems unlikely \[[@CIT0044]\]. Yukl et al \[[@CIT0043]\] showed that nonactivated latently infected CD4^+^ T cells show substantial transcription initiation that is subsequently blocked at the elongation, polyadenylation, and splicing steps. In addition, evidence indicates that unstimulated naive and memory CD4^+^ T-cell subsets support transcription initiation and elongation with different capacity; however, upon stimulation, T~EM~ cells are the cell subset that more efficiently achieves transcript elongation \[[@CIT0045]\]. Although we did not observe differences in the bulk distribution of CD4^+^ T-cell subsets from BSL to 12MPT, we cannot exclude modifications within particular T helper subsets that might justify the higher frequency of US-RNA-positive cells in periphery. The potential variations in T helper subsets could contribute to our findings as a consequence of increased transcription initiation, enhanced blockade, or even reduced trafficking of these cells to the tissues secondary to the changes of chemokines and chemokine receptors expression after HCV clearance. Moreover, HCV has been shown to replicate in lymphocytes \[[@CIT0046]\], thus HCV elimination might modify signaling pathways leading to increased HIV transcription in these cells. Finally, it has been demonstrated that DAA-mediated viral clearance was accompanied by a lower activity of type I IFN (α, γ, β) receptors, meaning a downregulation of IFN-stimulated genes, in HCV-monoinfected individuals \[[@CIT0011]\]. This might impact the transcriptional activity of HIV latently infected cells. A recent study showed that, in vitro, once latency is stablished, IFN-α could act as a reversal agent promoting viral replication \[[@CIT0047]\]. A priori, this result is in contrast with our findings. However, it should be noted that the establishment and maintenance of latency is a complex multifactorial phenomenon governed by mixed, sometimes opposed, mechanisms, and the net result of this is what is observed ex vivo.

CONCLUSIONS {#s10}
===========

This work opens new perspectives that should be addressed. First, we used PCR-based techniques to measure viral reservoirs. These assays tend to overestimate the frequency of replication competent virus, because both defective and nondefective viral strains are detected. The aim of future studies should include assays aimed at identifying the translation-competent reservoir \[[@CIT0048]\] as well as qVOA, TILDA (Tat/rev Induced Limiting Dilution Assay), and IPDA (intact proviral DNA assay) assays to address this limitation \[[@CIT0049], [@CIT0050]\]. Second, longer time of follow up would provide more information regarding the long-term effect of HCV clearance in HIV transcriptional activity. In addition, it would be relevant to evaluate the magnitude and quality of HIV-specific immune response after HCV clearance and its association with HIV persistence, because it could be hypothesized that the increase in HIV transcriptional activity might be associated with a boosting of HIV-specific T cells. Third, all of the individuals included in the present study presented advanced liver fibrosis; it will be important to evaluate whether the results found are reproducible in a cohort of participants with low to mild liver fibrosis. Finally, results could not be extended to the intrahepatic CD4^+^ T cells, but a similar or higher increase in HIV transcription is expected. There is certain evidence to suggest that hepatocytes and hepatic stellate cells support HIV infection \[[@CIT0051]\]. Thus, the modification in the liver environment, including decreased HCV-specific immune surveillance, could lead to a relapse in HIV transcription in these cells. Nevertheless, results presented here provide an important insight into the effects of chronic HCV infection on virus persistence, confirming HCV coinfection as a relevant factor imposing an extra challenge in HIV remission studies, even after HCV clearance.

Supplementary Data {#s11}
==================

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Supplementary File 1.** Detailed description of methods used in this manuscript.

**Supplementary Figure S1.** Cell-associated (CA) HIV US-RNA dynamics in HIV/HCV-coinfected individuals treated with DAA with or without ribavirin. Cell-associated HIV unspliced (US)-RNA was evaluated in coinfected individuals receiving DAA or DAA plus ribavirin (RBV), before treatment initiation (baseline \[BSL\]), at the end of treatment (EOT), and 12 months after finalizing therapy (12MPT). Viral DNA and RNA copies were calculated relative to 10^6^ cell equivalents (CE). Individual values, median and 25th and 75th percentiles, are indicated. Statistical comparisons were performed using Wilcoxon test; \*, *P*˂ 0.05.

**Supplementary Figure S2.** Gating strategy used for the identification of the studied cellular populations, by flow cytometry. To study immune phenotype of both NK and T cells, initial gating was performed on a forward scatter area (FSC-A) versus FSC-height (FSC-H) plot to remove doublets. Dead cells were then excluded on the bases of Zombie NIR fluorescence. Then, lymphocytes were selected in FSC versus side scatter (SSC) plot. Subsequently, CD3 expression was analyzed in a CD3 versus SSC-H dot plot (A). For NK analysis, CD3 and CD56 expression was analyzed on total lymphocytes. CD3^−^/CD56^+^ cells were selected. Then, expression of cellular markers of activation was studied. Representative flow cytometry plots for Nkp46, NKp30, NKG2D, CD69, and CD95 are shown (B). For identification of CD4^+^ and CD8^+^ T-cells, a CD8 versus CD4 dot plot was constructed. Expression of CD25, CD38, HLA-DR, CD127, and PD-1 on CD8^+^ cells is shown from 1 representative subject (C, top panel). To analyze the distribution of the different phenotype subsets on CD8^+^ T cells, CD45RO versus CCR7 dot plots were constructed and shown in C (bottom panel). Subsequently, CD28 and CD95 were used to define on (1) CCR7^+^/CD45RO^−^ gate, naive and stem cell memory (SCM) T-cells, (2) CCR7^+^/CD45RO^+^ gate, central memory T cells, (3) CCR7^−^/CD45RO^+^ gate,  transitional memory (TM) and effector memory T cells (EM), and (4) CCR7^−^/CD45RO^−^ gate,  terminal effector T cells (TE). Identical analysis was performed on the CD4^+^ T-cell subset (data not shown ).

**Supplementary Figure S3.** Distribution of memory subpopulations within CD4^+^ and CD8^+^ T-cells from HIV/HCV-coinfected individuals treated with DAA. Proportion of naive cells; stem cell memory (SCM), central memory (CM), transitional memory (TM), effector memory (EM), and terminal effector (TE) T cells were evaluated in CD4^+^ (A) or CD8^+^ T-cells (B) from coinfected individuals at baseline (BSL), end of treatment (EOT), and 12 months after finalizing DAA therapy (12MPT). The analyses were performed with SPICE software. In bar graphs, the color code shown at the bottom mirrors the one shown in the pies. Each dot represent individual values, boxes extend from 25th to 75th percentiles, and lines within boxes represent the median value.

**Supplementary Figure S4.** Immune marker expression in CD4^+^ T cells from HIV/HCV-coinfected individuals treated with DAA. Modulation of immune cell markers was evaluated before DAA therapy initiation (baseline \[BSL\]), at the end of treatment (EOT), and 12 months after finalizing DAA therapy (12MPT). Frequencies of CD38, HLA-DR, PD-1, CD38/HLA-DR, and CD38/HLA-DR/PD-1 positive CD4^+^ T cells are shown. CD25 and CD127 expression were also monitored, but no differences were found and thus no results are shown. (A). Analysis of distribution of CD4^+^ T-cell populations in terms of memory subsets was performed with SPICE software (B). Individual values are indicated. Boxes represent the IQR of 25--75, and horizontal lines within boxes represent the medians. *P* values were calculated using the Wilcoxon test. Asterisks denote different *P* values: \*, *P* ˂ 0.05; \*\*, *P* ˂ 0.01.

**Supplementary Figure S5.** Immune marker expression in CD8^+^ T cells from HIV/HCV-coinfected individuals treated with DAA. Modulation of immune cell markers was evaluated before DAA therapy initiation (baseline \[BSL\]), end of treatment (EOT), and 12 months after finalizing DAA therapy (12MPT). Frequencies of CD38, HLA-DR, CD38/HLA-DR, and CD38/HLA-DR/PD-1 positive CD8^+^ T cells are shown. CD25 and CD127 expression were also monitored, but no differences were found and thus no results are shown. (A). Analysis of distribution of CD8^+^ T-cell populations in terms of memory subsets was performed with SPICE software (B). Individual values are indicated. Boxes represent the IQR of 25--75, and horizontal lines within boxes represent the medians. *P* values were calculated using the Wilcoxon test. Asterisks denote different *P* values: \*, *P* ˂ 0.05; \*\*, *P* ˂ 0.01; \*\*\*, *P*˂ 0.001.

**Supplementary Figure S6.** Study of NK cell activation in HIV/HCV-coinfected individuals treated with DAA therapy. NK cell immune profile was assessed in coinfected individuals at BSL, EOT, and 12MPT. Frequencies of CD38 (A), HLA-DR (B), CD95 (D), CD69 (E), CD25 (F), and NKG2D, Nkp30, and NKp46 positive NK cells (H) are shown. Analysis of distribution of NK cells subsets in terms of HLA-DR/CD38 (C) and CD25/CD69/CD95 expression (G) was performed with SPICE software. Relative fluorescence intensity (RFI) for NKG2D, Nkp30, and NKp46 stains on NK cells (H, right panel) are shown. Individual values are indicated. Boxes represent the IQR of 25--75, and horizontal lines within boxes represent the medians. *P* values were calculated using Wilcoxon test. Asterisks denote different *P* values: \*, *P* ˂ 0.05; \*\* *P* ˂ 0.01; \*\*\*, *P* ˂ 0.001.

**Supplementary Figure S7.** Evaluation of soluble markers of immune activation and inflammation in HIV/HCV-coinfected individuals treated with DAA therapy. Plasma from coinfected individuals was evaluated before DAA therapy initiation (baseline \[BSL\]), at the end of treatment (EOT), and after 12 months of DAA therapy finalization (12MPT). Plasma IL-6 (A), IL-2 (B), sCD14 (C), TNF-α (D), IFN-γ (E), sCD23 (F), IP-10 (G), IL-8 (H), sICAM (I), and sCD163 (J) levels are indicated. Boxes represent the IQR of 25--75, whiskers extend from minimum to maximum, and horizontal lines within boxes represent the medians. *P* values were calculated using Wilcoxon test. Asterisks denote different *P* values: \*, *P* ˂ 0.05; \*\*, *P* ˂ 0.01; \*\*\*, *P* ˂ 0.001.
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